Researchers bust a gut to improve gastrointestinal disorders market

Drugs to treat gastrointestinal disorders are due to see a significant price drop, as patents run out and research takes off, according to a new report by health care experts GBI Research.

The new report states that patients with disorders such as irritable bowel syndrome (IBS), Crohn’s disease, ulcerative colitis (UC), gastroesophageal reflux disease (GERD) and peptic ulcer disease (PUD) will experience a rush in new generic versions of popular medication, and new novel drugs with the hope of better results.

The market for gastrointestinal disorder therapeutics is being driven by increased stress, unhealthy eating habits, the growth of the global elderly population and an increased level of awareness among the general population, which has spurred on the rise of incidence and diagnosis over the recent past. Anxiety, unhealthy foods and advanced age can all be associated with changes in gastrointestinal physiology. However, gastrointestinal diseases still have a low diagnosis rate, and a fear of serious side effects may restrain market growth, the report points out.